Skye Bioscience (SKYE) Non-Current Deffered Revenue (2014 - 2016)
Skye Bioscience (SKYE) posted quarterly Non-Current Deffered Revenue of $3256.0 for Q2 2016, little changed quarter-over-quarter from $3244.0 in Q1 2016.
Skye Bioscience (SKYE) Non-Current Deffered Revenue (2014 - 2016) Analysis & Trends
Skye Bioscience (SKYE) has reported Non-Current Deffered Revenue for 3 consecutive years, with $3256.0 the latest figure, recorded in Q2 2016.
- In Q2 2016, Non-Current Deffered Revenue changed N/A year-over-year to $3256.0; the TTM figure through Jun 2016 stood at $3256.0 (changed N/A YoY), while the FY2015 annual figure was $3233.0, up 301.61% from the prior year.
- Non-Current Deffered Revenue was little changed at $3256.0 in Q2 2016 per SKYE's latest filing, from $3244.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $3256.0 in Q2 2016 and bottomed at $805.0 in Q4 2014.
- Historically, Non-Current Deffered Revenue has averaged $2751.8 across 3 years, with a median of $3233.0 in 2015.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 301.61% in 2015 and fell as far as 301.61% in 2015.
- Skye Bioscience's Non-Current Deffered Revenue stood at $805.0 in 2014, then soared by 301.61% to $3233.0 in 2015, then rose by 0.71% to $3256.0 in 2016.
- Business Quant data shows SKYE's Non-Current Deffered Revenue at $3256.0 in Q2 2016, $3244.0 in Q1 2016, and $3233.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 3,256.00 |
| Mar 31, 2016 | 3,244.00 |
| Dec 31, 2015 | 3,233.00 |
| Sep 30, 2015 | 3,221.00 |
| Dec 31, 2014 | 805.00 |